A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients With Ulcerative Colitis  Maria Theresa Arias, Niels Vande Casteele, Séverine Vermeire, Anthony de Buck van Overstraeten, Thomas Billiet, Filip Baert, Albert Wolthuis, Gert Van Assche, Maja Noman, Ilse Hoffman, Andre D’Hoore, Ann Gils, Paul Rutgeerts, Marc Ferrante  Clinical Gastroenterology and Hepatology  Volume 13, Issue 3, Pages 531-538 (March 2015) DOI: 10.1016/j.cgh.2014.07.055 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Relapse-free and colectomy-free survival. (A) Overall relapse-free survival in 184 patients on maintenance therapy with IFX, and (B) overall colectomy-free survival in 285 patients treated with infliximab for refractory ulcerative colitis. Clinical Gastroenterology and Hepatology 2015 13, 531-538DOI: (10.1016/j.cgh.2014.07.055) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Predictive role of infliximab serum levels at week 14. (A) Relapse-free and (B) colectomy-free survival based on infliximab serum levels at week 14. Clinical Gastroenterology and Hepatology 2015 13, 531-538DOI: (10.1016/j.cgh.2014.07.055) Copyright © 2015 AGA Institute Terms and Conditions

Figure 3 Predictive role of risk panel. Relapse and colectomy rate based on a risk panel including 5 independent risk factors, namely absence of short-term complete clinical response, absence of short-term mucosal healing, pANCA positivity, baseline albumin level less than 35 g/L, and baseline CRP level greater than 5 mg/L: (A) time to relapse, (B) time to colectomy, (C) clinical relapse rate within 12 months, and (D) colectomy rate within 60 months. Clinical Gastroenterology and Hepatology 2015 13, 531-538DOI: (10.1016/j.cgh.2014.07.055) Copyright © 2015 AGA Institute Terms and Conditions